GR78465B - - Google Patents

Info

Publication number
GR78465B
GR78465B GR70610A GR830170610A GR78465B GR 78465 B GR78465 B GR 78465B GR 70610 A GR70610 A GR 70610A GR 830170610 A GR830170610 A GR 830170610A GR 78465 B GR78465 B GR 78465B
Authority
GR
Greece
Application number
GR70610A
Inventor
Philibert Daniel
Teutsch Jean Georges
Costerousse Germain
Deraedt Roger
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of GR78465B publication Critical patent/GR78465B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C07J7/003—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/0075—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
GR70610A 1982-03-01 1983-02-25 GR78465B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8203338A FR2522328B1 (fr) 1982-03-01 1982-03-01 Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments

Publications (1)

Publication Number Publication Date
GR78465B true GR78465B (el) 1984-09-27

Family

ID=9271439

Family Applications (1)

Application Number Title Priority Date Filing Date
GR70610A GR78465B (el) 1982-03-01 1983-02-25

Country Status (32)

Country Link
US (2) US4477445A (el)
JP (2) JPS58201800A (el)
KR (1) KR880001870B1 (el)
AR (1) AR241187A1 (el)
AT (1) AT396109B (el)
AU (1) AU562739B2 (el)
BE (1) BE896042A (el)
CA (1) CA1206471A (el)
CH (1) CH657368A5 (el)
DE (1) DE3307143A1 (el)
DK (1) DK89783A (el)
EG (1) EG15881A (el)
ES (1) ES520195A0 (el)
FI (1) FI80049C (el)
FR (1) FR2522328B1 (el)
GB (1) GB2118186B (el)
GR (1) GR78465B (el)
HU (1) HU193269B (el)
IE (1) IE54748B1 (el)
IL (1) IL67920A0 (el)
IT (1) IT1197592B (el)
LU (1) LU84667A1 (el)
MA (1) MA19716A1 (el)
MX (1) MX7199E (el)
NL (1) NL8300738A (el)
PH (1) PH21308A (el)
PT (1) PT76307B (el)
SE (1) SE8300308L (el)
SU (1) SU1340593A3 (el)
WO (1) WO1983003099A1 (el)
YU (1) YU47883A (el)
ZA (1) ZA83982B (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US5182381A (en) * 1982-03-01 1993-01-26 Roussel Ulcaf Intermediates for 3-keto-19-nor-Δ4,9 -steroids
FR2639045B2 (fr) * 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
DE3231827A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-17(alpha)-alkinyl-17ss-hydroxy-4,9(10)- estradien-3-on-derivate, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3461090D1 (en) * 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
IT1212835B (it) * 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4666898A (en) * 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
DE3410880A1 (de) * 1984-03-21 1985-10-03 Schering AG, Berlin und Bergkamen, 1000 Berlin 17-substituierte estradiene und estratriene
DE3438500C1 (de) * 1984-10-18 1986-05-28 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung 11ß-substituierter Δ↑9↑-19-Norsteroide
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
FR2576025B1 (fr) * 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
NZ214998A (en) * 1985-02-07 1989-06-28 Schering Ag 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions
GB8513723D0 (en) * 1985-05-31 1985-07-03 Erba Farmitalia 11-beta substituted steroids
CA1241947A (en) * 1985-05-31 1988-09-13 Pierre R. Proulx Conjugated polyene sterol derivatives as membrane probes
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2610933B1 (fr) * 1987-02-18 1989-06-09 Roussel Uclaf Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
US5075464A (en) * 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) * 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
FR2620707B1 (fr) * 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
JPH02188599A (ja) * 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
US6790971B1 (en) * 1989-02-24 2004-09-14 Aventis Pharma S.A. 19-Nor-steroids
FR2665901B2 (fr) * 1989-02-24 1994-07-29 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine carbonee comportant une fonction amide, leur preparation, leur application comme medicaments.
FR2643638B1 (fr) * 1989-02-24 1991-06-14 Roussel Uclaf Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ES2127181T3 (es) * 1989-08-04 1999-04-16 Schering Ag 11-beta-aril-gona-4,9-dien-3-onas.
US5276023A (en) * 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651435A1 (fr) * 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
FR2659233B1 (fr) * 1990-03-06 1994-01-21 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage.
DE4008584A1 (de) * 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
JP3029907B2 (ja) * 1991-12-20 2000-04-10 理化学研究所 抗肥満剤
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
EP0683172B1 (en) * 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1997041145A1 (en) 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
US6531462B2 (en) 1997-11-06 2003-03-11 Riken Medicament for treating obesity and improving lipid metabolism
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
ES2546336T3 (es) * 2000-03-17 2015-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 19-norpregnadienodiona 17-alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida como agentes antiprogestacionales
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
WO2004078709A2 (en) * 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES
AU2004249280A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Antiviral compositions and methods of using the same
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
KR20130009990A (ko) * 2010-03-22 2013-01-24 레프로스 쎄라피우틱스 아이엔씨. 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들
EP2576582B1 (en) 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
CA2872644A1 (en) 2012-05-31 2013-12-05 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
ES2688821T3 (es) 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona
US10919929B2 (en) 2013-12-11 2021-02-16 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
AU2016377702B2 (en) 2015-12-23 2021-03-11 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3394079A4 (en) 2015-12-23 2019-08-21 Oric Pharmaceuticals, Inc. INHIBITORS OF GLUCOCORTICOIDREZEPTORS
MX2018008849A (es) 2016-01-19 2019-01-31 Corcept Therapeutics Inc Diagnostico diferencial de sindrome de cushing ectopico.
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
EP3641780A4 (en) 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH571537A5 (el) * 1970-04-24 1976-01-15 Sandoz Ag
CH558346A (de) * 1971-06-17 1975-01-31 Sandoz Ag Verfahren zur herstellung neuer 3-oximino-17(alpha)-propadienyl-substituierter steroide.
BE787898A (fr) * 1971-08-26 1973-02-23 Roussel Uclaf Nouveaux composes steroides trieniques et procede de preparation
DE2636405C2 (de) * 1976-08-12 1982-07-08 Schering Ag, 1000 Berlin Und 4619 Bergkamen Δ↑1↑↑5↑-17α-Chloräthinyl- und -Propinylsteroide der Östranreihe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
FR2377417A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides substitues en 11b, ainsi que leur procede de preparation
FR2495621A1 (fr) * 1980-12-05 1982-06-11 Roussel Uclaf Nouveaux derives de l'estra 4,9-diene, leur procede de preparation et leur application comme medicaments
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

Also Published As

Publication number Publication date
JPH054397B2 (el) 1993-01-19
GB2118186B (en) 1986-04-23
LU84667A1 (fr) 1983-09-08
AU562739B2 (en) 1987-06-18
WO1983003099A1 (en) 1983-09-15
FI830652L (fi) 1983-09-02
CA1206471A (fr) 1986-06-24
ATA71183A (de) 1992-10-15
JPS58201800A (ja) 1983-11-24
IL67920A0 (en) 1983-06-15
ES8401495A1 (es) 1983-12-01
JPH02275895A (ja) 1990-11-09
GB2118186A (en) 1983-10-26
NL8300738A (nl) 1983-10-03
SE8300308D0 (sv) 1983-01-21
SU1340593A3 (ru) 1987-09-23
US4540686A (en) 1985-09-10
PT76307B (fr) 1986-01-27
HU193269B (en) 1987-09-28
GB8305558D0 (en) 1983-03-30
MX7199E (es) 1987-12-23
AT396109B (de) 1993-06-25
EG15881A (en) 1991-06-30
KR840003649A (ko) 1984-09-15
PH21308A (en) 1987-09-28
IE830429L (en) 1983-09-01
FR2522328A1 (fr) 1983-09-02
BE896042A (fr) 1983-08-29
DE3307143A1 (de) 1983-09-08
JPH0443920B2 (el) 1992-07-20
ES520195A0 (es) 1983-12-01
CH657368A5 (fr) 1986-08-29
US4477445A (en) 1984-10-16
MA19716A1 (fr) 1983-10-01
AR241187A1 (es) 1992-01-31
FI830652A0 (fi) 1983-02-28
IT1197592B (it) 1988-12-06
PT76307A (fr) 1983-03-01
IE54748B1 (en) 1990-01-31
AU1191383A (en) 1983-09-08
SE8300308L (sv) 1983-09-02
YU47883A (en) 1986-04-30
IT8347820A0 (it) 1983-02-28
DK89783D0 (da) 1983-02-25
ZA83982B (en) 1984-03-28
FI80049C (fi) 1990-04-10
KR880001870B1 (ko) 1988-09-23
FR2522328B1 (fr) 1986-02-14
DK89783A (da) 1983-09-02
FI80049B (fi) 1989-12-29

Similar Documents

Publication Publication Date Title
DE3336265C2 (el)
FR2523892B1 (el)
GR78465B (el)
DE3334919C2 (el)
DE3332617C2 (el)
FR2521758B1 (el)
FR2524247B1 (el)
DE3326147C2 (el)
DE3342311C2 (el)
DE3335107C2 (el)
DE3348339A1 (el)
DE3234082C2 (el)
DE3378493D1 (el)
DE3315521C2 (el)
FR2520073B1 (el)
FR2522284B1 (el)
DE3225820C2 (el)
DE8221839U1 (el)
DE3244944C2 (el)
DE3313122C2 (el)
FR2523979B1 (el)
FR2520460B1 (el)
DE3245382C2 (el)
FR2511229B1 (el)
FR2519964B1 (el)